The Power to Inactivate Pathogens is Now in Your Hands

Filtered Far UV-C is a breakthrough, disruptive technology developed by a team of researchers led by David Brenner, PhD, director of the Center for Radiological Research at Columbia University. It has been extensively tested and endorsed by leading institutions across the world in peer-reviewed, scientific journals. Studies have shown the technology has the same efficacy as conventional UV-C and is scientifically tested technology shown to be safe to use when used within the current American Conference of Governmental Hygienists (ACGIH) dose limits when humans are present because it does not penetrate the layer of dead cells on skin or the tear layer of the eye. 

This discovery has become known as filtered Far UV-C, utilizing filtered 222-nm light, and Columbia University secured its first issued patent for filtered Far UV-C in 2018. Tokyo-based lighting giant Ushio Inc. has exclusive license to Columbia’s patents, and has begun manufacturing high-efficacy, filtered Far UV-C lamps. 

BeamClean™ is a newly patented use of this technology that is portable, handheld and inactivates pathogens on commonly touched surfaces in seconds. Benefits include:

• Inactivates pathogens in seconds – including COVID-19 
• Safe on human skin and eyes in occupied settings when used within ACGIH dose limits
• Efficacy and safety endorsed in peer-reviewed scientific journals 
• Handheld, portable, rechargeable, and lightweight 
• Everyday use: commonly touched surfaces - doors, handles, tables, railings, electronics, food, upholstery, fabrics, bedding, skin 
• No chemicals, and is environmentally friendly 

BeamClean™ has been made possible by having a development and commercialization agreement with Ushio America, Inc. and applying their existing Care222® technology into BeamClean™. 

Studies have shown that BeamClean™ with Care222® inactivates pathogens such as coronavirus, Influenza, E. coli, Salmonella and more, from commonly touched surfaces in seconds; and when used within ACGIH dose limits, this can be achieved in a way that is safe on human skin and eyes in occupied settings.

Freestyle Partners, LLC is currently in discussions with launch partners to help bring its innovative portable, handheld device to market.